Key Points
- Shares of Sigma Healthcare (SIG) declined by as much as 5.5% to A$2.76 following confirmation of early-stage acquisition discussions
- The proposed transaction for Boots could exceed $10 billion in value, with Sigma facing competition from Canada’s Weston family
- Sycamore Partners, the current owner of Boots, is pursuing a sale of the British pharmacy network, which operates more than 1,800 UK locations
- If completed, the transaction would eliminate Boots’ previously planned London stock market listing
- Sigma currently maintains a British presence through its collaboration with Greenlight Healthcare, launching Chemist Warehouse locations throughout London
Shares of Sigma Healthcare (SIG) tumbled by as much as 5.5% to A$2.76 during Wednesday trading after the Australian pharmaceutical company acknowledged it has commenced early-stage negotiations regarding the acquisition of British pharmacy retailer Boots.
Sigma Healthcare Limited, SIG.AX
The acknowledgment arrived through an Australian Securities Exchange disclosure, where Sigma stated it had “engaged in preliminary discussions in relation to the sale process.” The firm emphasized that “there is no certainty that any transaction will eventuate.”
The potential acquisition, initially disclosed by the Financial Times, could place Boots’ valuation above $10 billion. Sigma faces competition in the bidding process — the Weston family from Canada, who control Loblaw, are also reportedly pursuing the opportunity.
Boots currently belongs to Sycamore Partners, a private equity firm based in the United States. The pharmacy network maintains more than 1,800 locations throughout the UK and has operations spanning 11 nations, including Ireland, Mexico, and Thailand, with a combined total of 3,776 retail outlets as of August last year.
A finalized acquisition would terminate Boots’ intentions for an initial public offering in London, the Financial Times reported.
Sigma’s pursuit of Boots aligns with the company’s expanding international strategy. In recent weeks, the organization established a partnership with British pharmacy operator Greenlight Healthcare to introduce Chemist Warehouse-branded outlets throughout London and assist Greenlight’s 22 current stores with supply chain logistics and promotional activities.
Chemist Warehouse Financial Power
The British expansion benefits from substantial Australian financial backing. Sigma’s principal shareholders include billionaire siblings Jack and Sam Gance, along with their associate Mario Verrochi — the founding team behind Chemist Warehouse.
Verrochi possesses a current net worth of $5.5 billion. Jack Gance holds assets valued at $3.4 billion, while Sam Gance’s wealth stands at $3.2 billion, based on Forbes calculations.
During February 2025, Chemist Warehouse completed a merger with Sigma Healthcare through a transaction that established a pharmaceutical enterprise valued above $22 billion. The unified organization currently operates more than 950 retail locations spanning Australia, China, Dubai, Ireland, and New Zealand.
Implications of a Boots Acquisition for Sigma
Boots represents considerably more than a modest addition. With nearly 3,800 global locations and franchise arrangements extending into the Middle East and Indonesia, the acquisition would fundamentally transform Sigma’s business.
The organization has not revealed specific details regarding its potential offer, nor has it disclosed whether financial partners are involved in structuring a transaction of this magnitude.
Sigma’s market performance on Wednesday demonstrates investor uncertainty. A deal exceeding $10 billion would substantially surpass any previous transaction the company has undertaken, and the final result remains highly uncertain.
The company indicated it would provide market updates should any significant developments occur.
